Adult Attention Deficit Hyperactivity Disorder (ADHD)

1. Clinical Overview

Summary

Adult ADHD is a persistent neurodevelopmental disorder characterised by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity that cause significant functional impairment across multiple life domains. [1] Although historically considered a childhood disorder that resolves with maturation, prospective longitudinal studies demonstrate that 50-65% of individuals diagnosed in childhood continue to experience clinically significant symptoms into adulthood. [2] The worldwide prevalence of adult ADHD is estimated at 2.5-4.4%, making it one of the most common psychiatric conditions in adults. [3]

DSM-5 criteria require that symptoms must have been present before age 12, representing a critical diagnostic requirement that distinguishes ADHD from acquired attention difficulties. [4] This childhood onset criterion necessitates retrospective assessment in adults presenting for diagnosis, often requiring collateral information from parents, school reports, or other informants. Adult ADHD frequently presents differently from childhood ADHD, with hyperactivity transforming into inner restlessness, and executive dysfunction, emotional dysregulation, and time-management difficulties becoming more prominent than overt behavioural symptoms.

Treatment of adult ADHD is highly effective, with 70-80% of patients responding to pharmacotherapy. [5] Stimulant medications (methylphenidate, lisdexamfetamine, dexamfetamine) remain first-line treatment, with lisdexamfetamine recommended as first-line in adults by NICE guidelines. [6] Non-stimulant options (atomoxetine, guanfacine) provide alternatives for patients with contraindications, substance misuse concerns, or inadequate response to stimulants. Psychological interventions, particularly cognitive behavioural therapy adapted for ADHD, provide adjunctive benefits for residual symptoms and comorbid conditions.

Key Facts

Clinical Pearls

The Childhood Symptom Requirement Is Non-Negotiable: DSM-5 requires symptoms present before age 12. Adults presenting with new-onset attention difficulties after age 12 do NOT have ADHD—investigate other causes including anxiety, depression, sleep disorders, substance use, or medical conditions.

Girls Become Women With Undiagnosed ADHD: The 3:1 male predominance in childhood narrows to near 1:1 in adult diagnoses. This reflects systematic underdiagnosis of females who present with inattentive subtype, internalising symptoms, and compensatory strategies that mask impairment until life demands increase. [7]

Treat the ADHD, Reduce the Comorbidity: Many comorbid conditions (anxiety, depression, substance use) improve when core ADHD symptoms are effectively treated. Treating ADHD does not worsen genuine comorbid conditions—stimulants are not contraindicated in anxiety if ADHD is also present. [10]

Executive Dysfunction Is the Hidden Core: Difficulty with planning, organisation, time estimation, working memory, and emotional regulation often causes more impairment than the DSM criteria suggest. Patients describe "time blindness" and "rejection sensitive dysphoria" as disabling features not captured by symptom lists.

Why This Matters Clinically

Untreated adult ADHD is associated with substantially increased risks of unemployment, job instability, reduced income, relationship breakdown, divorce, motor vehicle accidents, substance use disorders, and premature mortality. [11,12] Adults with untreated ADHD are 3-4 times more likely to have traffic accidents and 1.5-2 times more likely to develop substance use disorders. Educational underachievement is near-universal, with many patients reporting they never reached their intellectual potential.

The economic burden of adult ADHD is substantial, with estimated annual costs of £5,000-10,000 per patient in lost productivity, healthcare utilisation, and criminal justice involvement. [13] Effective treatment improves quality of life, occupational functioning, relationship stability, and reduces healthcare costs. Despite this, adult ADHD remains underdiagnosed and undertreated, with only 10-25% of affected adults receiving appropriate treatment.

---

2. Epidemiology

Incidence & Prevalence

Demographics

Risk Factors

Non-Modifiable Risk Factors:

Modifiable Risk Factors:

---

3. Pathophysiology

Neurobiological Basis

Genetic Architecture:

ADHD is highly heritable (70-80%), with genetic factors explaining more variance than any other psychiatric disorder except autism. [8] The genetic architecture is polygenic, with genome-wide association studies identifying multiple common variants of small effect. Key implicated genes include:

• DAT1 (SLC6A3): Dopamine transporter gene—10-repeat allele associated with ADHD
• DRD4: Dopamine D4 receptor—7-repeat allele associated with increased risk
• DRD5: Dopamine D5 receptor
• SNAP25: Synaptosomal-associated protein—involved in neurotransmitter release
• COMT: Catechol-O-methyltransferase—dopamine degradation

Exam Detail: Molecular Pathophysiology:

The catecholamine hypothesis of ADHD proposes that reduced dopaminergic and noradrenergic neurotransmission in prefrontal cortex circuits underlies core symptoms. [15] Evidence supporting this includes:

1. Dopamine transporter (DAT) upregulation: PET studies show increased DAT density in striatum of ADHD patients
2. Reduced dopamine synthesis: Lower DOPA decarboxylase activity
3. Stimulant mechanism: Methylphenidate and amphetamines increase synaptic dopamine/noradrenaline
4. Atomoxetine mechanism: Selective noradrenaline reuptake inhibition

Prefrontal cortex dopamine follows an inverted U-shaped curve—too little or too much impairs function. ADHD represents suboptimal dopamine signalling, and stimulants normalise this rather than causing supranormal enhancement.

Neuroanatomical Differences:

Structural MRI studies consistently demonstrate:

Delayed Cortical Maturation:

Longitudinal studies show that ADHD involves delayed rather than deviant cortical development. Peak cortical thickness is reached approximately 3 years later in ADHD (age 10.5 vs 7.5 years). [16] This delay is most pronounced in prefrontal regions critical for attention and executive function. Some improvement with age may reflect gradual catch-up of cortical maturation.

DSM-5 Classification

Presentation Specifiers:

Severity Specifiers:

• Mild: Few symptoms beyond threshold; minor functional impairment
• Moderate: Symptoms and impairment between mild and severe
• Severe: Many symptoms beyond threshold; marked impairment in multiple domains

DSM-5 Diagnostic Criteria (Adult Modification)

A. Symptom Criteria (≥5 symptoms in either/both domains, persisting ≥6 months):

Inattention Domain:

1. Fails to give close attention to detail; makes careless errors in work
2. Difficulty sustaining attention in tasks or leisure activities
3. Does not seem to listen when spoken to directly
4. Fails to follow through on instructions; fails to finish work duties
5. Difficulty organising tasks and activities
6. Avoids or is reluctant to engage in tasks requiring sustained mental effort
7. Loses things necessary for tasks and activities
8. Easily distracted by extraneous stimuli (including unrelated thoughts in adults)
9. Forgetful in daily activities (keeping appointments, returning calls)

Hyperactivity-Impulsivity Domain:

1. Fidgets or taps hands/feet; squirms in seat
2. Leaves seat in situations where remaining seated expected
3. Subjective feelings of restlessness (adults); runs/climbs in children
4. Unable to engage quietly in leisure activities
5. "On the go" or "driven by a motor"; uncomfortable being still for extended time
6. Talks excessively
7. Blurts out answers before question completed; completes others' sentences
8. Difficulty waiting turn (e.g., waiting in line)
9. Interrupts or intrudes on others; may take over what others are doing

B. Onset Criterion: Several symptoms present before age 12 years

C. Pervasiveness: Symptoms present in two or more settings (work, home, social)

D. Functional Impairment: Clear evidence symptoms interfere with quality of social, academic, or occupational functioning

E. Exclusion: Symptoms not better explained by another mental disorder (mood disorder, anxiety disorder, dissociative disorder, personality disorder, substance intoxication/withdrawal)

---

4. Clinical Presentation

Adult-Specific Symptom Presentation

Adult ADHD often presents differently from childhood ADHD, with hyperactivity becoming less overt and executive dysfunction more prominent:

Inattention in Adults:

• Chronic underachievement ("never reached potential")
• Difficulty completing administrative tasks (taxes, forms, bills)
• Losing or misplacing important items frequently
• Missing deadlines despite adequate ability
• Difficulty following conversations; mind wandering
• Starting many projects; completing few
• Poor time estimation ("time blindness")
• Needing external deadlines to function

Hyperactivity in Adults:

• Inner restlessness rather than overt motor activity
• Difficulty relaxing; always needing to be doing something
• Choosing highly active jobs or hobbies
• Fidgeting, leg bouncing, pen tapping
• Discomfort in sedentary situations (long meetings, flights)
• Talking excessively; difficulty listening

Impulsivity in Adults:

• Impulsive spending and financial problems
• Impulsive job changes; frequent career switches
• Relationship difficulties; impulsive relationship decisions
• Traffic violations; speeding; accidents
• Interrupting others; difficulty waiting turn
• Making important decisions without adequate reflection
• Substance use as impulsive behaviour

Executive Dysfunction (Core Feature Often Missed)

Emotional Dysregulation

Emotional dysregulation is increasingly recognised as a core ADHD feature, though not included in DSM-5 criteria:

• Low frustration tolerance: Quick to anger; irritability
• Emotional impulsivity: Acting on emotions without reflection
• Mood lability: Rapid mood shifts (distinct from bipolar cycling)
• Rejection sensitive dysphoria: Intense emotional response to perceived rejection
• Difficulty calming down: Prolonged emotional recovery

Atypical and Masked Presentations

High-Functioning/Compensated ADHD:

• High IQ masks impairment until demands increase
• Excessive effort to maintain normal function
• Burnout, anxiety, depression as presenting complaints
• Diagnosis often after child diagnosed

Female-Pattern Presentation:

• Inattentive subtype predominates
• Internalising rather than externalising behaviours
• Anxiety and depression as primary complaints
• Socially appropriate behaviour masks hyperactivity
• Diagnosed much later than males (mean age 36-40) [7]

Late-Life Presentation:

• Cognitive decline accelerates ADHD impairment
• May mimic mild cognitive impairment
• Stimulants may help and clarify diagnosis

Red Flags Requiring Careful Assessment

[!CAUTION] Assess Carefully Before Treatment:

• Substance misuse history: Assess abuse potential; consider non-stimulants first
• Cardiovascular disease: Full cardiac assessment before stimulants
• Psychotic symptoms: Rule out or stabilise before stimulants
• Uncontrolled hypertension: Treat BP before stimulant initiation
• Severe anxiety: May worsen initially with stimulants; start low
• Eating disorders: Stimulant appetite suppression problematic
• Pregnancy: Risk-benefit discussion; limited data on stimulants

---

5. Differential Diagnosis

Critical Differential Diagnoses

The differential diagnosis of adult ADHD is broad, and accurate diagnosis requires careful consideration of conditions that can mimic or co-occur with ADHD:

ADHD vs Anxiety: Key Differentiators

ADHD vs Bipolar Disorder: Key Differentiators

Clinical Pearl: Comorbidity Is the Rule, Not the Exception: 60-80% of adults with ADHD have at least one comorbid psychiatric disorder. [9] ADHD frequently co-occurs with:

• Anxiety disorders (25-50%)
• Major depression (20-30%)
• Bipolar disorder (10-20%)
• Substance use disorders (25-50%)
• Personality disorders (20-30%)
• Autism spectrum disorder (20-30%)

When comorbidity is present, treat both conditions. Do not assume one explains the other.

ADHD vs Substance Use: Differentiating vs Comorbidity

---

6. Clinical Assessment

Diagnostic Assessment Framework

Comprehensive Assessment Components:

1. Clinical Interview (Patient)

   • Current symptoms and functional impairment
   • Symptom trajectory across lifespan
   • Childhood history (critical for onset criterion)
   • Educational and occupational history
   • Relationship history
   • Substance use history
   • Psychiatric history and comorbidity screen

2. Collateral Information (Essential)

   • Parent/sibling interview about childhood
   • School reports (often highly informative)
   • Partner/spouse perspective on current function
   • Work performance records if available

3. Standardised Rating Scales

4. Physical Examination
   • Height and weight (baseline before stimulants)
   • Blood pressure and heart rate (essential pre-treatment)
   • Cardiovascular examination
   • Neurological examination if indicated

Pre-Treatment Medical Assessment

Cardiovascular Assessment Before Stimulants

Exam Detail: Cardiovascular Risk Stratification:

All patients require:

• Personal cardiac history (murmurs, palpitations, syncope, chest pain)
• Family history (sudden death less than 40 years, cardiomyopathy, arrhythmias)
• Blood pressure and heart rate measurement

ECG indicated if:

• Personal history of cardiac disease or symptoms
• Family history of sudden death in first-degree relative less than 40 years
• Family history of cardiomyopathy or channelopathy
• Abnormal cardiac examination
• Planning high-dose stimulant treatment

Echo indicated if:

• Structural heart disease suspected
• Abnormal ECG findings

Stimulants are contraindicated in:

• Severe hypertension (> 160/100 mmHg untreated)
• Structural cardiac abnormalities with haemodynamic significance
• Symptomatic cardiovascular disease
• Previous serious cardiac arrhythmia

Abuse Potential Assessment

---

7. Management

Management Algorithm

ADULT ADHD DIAGNOSIS CONFIRMED
            ↓
[Pre-treatment Assessment]
• BP, HR, cardiac history, ECG if indicated
• Comorbidity screen
• Abuse potential assessment
• Baseline rating scales
            ↓
[NICE First-Line: LISDEXAMFETAMINE]
Start: 30mg daily (morning)
Titrate: 20mg increments weekly
Target: 30-70mg daily
            ↓
         Response?
        ↙        ↘
      YES         NO/Partial
       ↓              ↓
  Continue      [Switch to Methylphenidate]
  Monitoring    Long-acting: 18-72mg
                Short-acting: 5-20mg TDS
                        ↓
                   Response?
                  ↙        ↘
                YES         NO
                 ↓           ↓
            Continue   [Non-Stimulant]
                       Atomoxetine or
                       Guanfacine
                            ↓
                    Add Psychological
                    Interventions

Pharmacological Treatment

First-Line: Stimulant Medications

NICE Guidance (NG87) - Key Recommendations:

1. Lisdexamfetamine is first-line for adults (unless contraindicated)
2. Methylphenidate is alternative first-line if lisdexamfetamine unsuitable
3. Titrate to optimal dose based on efficacy and tolerability
4. Non-stimulants if stimulants contraindicated, not tolerated, or ineffective

Exam Detail: Stimulant Pharmacology:

Methylphenidate:

• Mechanism: Blocks dopamine and noradrenaline reuptake (DAT and NET inhibition)
• Does NOT release stored catecholamines (unlike amphetamines)
• Minimal effect on serotonin
• Metabolised by carboxylesterase (not CYP450); few drug interactions

Amphetamines (Lisdexamfetamine, Dexamfetamine):

• Mechanism: Multiple actions—DAT/NET inhibition, vesicular release, MAO inhibition
• Lisdexamfetamine is prodrug converted to dexamfetamine in RBCs
• Prodrug nature provides smoother pharmacokinetics and reduced abuse potential
• More potent than methylphenidate mg-for-mg

Comparative Efficacy: Network meta-analysis (Cortese et al. 2018) [5]:

• Amphetamines showed highest efficacy (SMD 0.79)
• Methylphenidate second (SMD 0.49)
• Atomoxetine third (SMD 0.45)

Second-Line: Non-Stimulant Medications

Non-Stimulant Indications:

• Contraindication to stimulants (cardiovascular, substance abuse)
• Stimulant intolerance
• Inadequate stimulant response
• Patient preference
• Prominent comorbid anxiety or tics

Titration Protocol

Lisdexamfetamine:

• Week 1: 30mg OD
• Week 2: 50mg OD (if tolerated and insufficient response)
• Week 3+: 70mg OD (maximum licensed dose)
• Assess response and side effects weekly during titration

Methylphenidate MR:

• Week 1: 18mg OD
• Week 2: 36mg OD
• Week 3: 54mg OD
• Week 4+: 72mg OD (maximum)

Common Side Effects and Management

Monitoring on Treatment

Psychological Interventions

Cognitive Behavioural Therapy for ADHD:

• Targets maladaptive thinking patterns
• Develops organisational skills and strategies
• Addresses procrastination and avoidance
• Manages emotional dysregulation
• Evidence: Moderate effect size as adjunct to medication [18]

ADHD Coaching:

• Practical strategies for daily functioning
• Goal-setting and accountability
• Time management techniques
• Organisational systems

Psychoeducation:

• Understanding ADHD neurobiology
• Reducing self-blame and shame
• Family education and relationship support
• Workplace accommodation strategies

Special Populations

Pregnancy:

• Limited safety data for stimulants
• Stop or minimise before conception where possible
• Risk-benefit discussion if treatment essential
• Methylphenidate has more safety data than amphetamines
• Atomoxetine: insufficient pregnancy data

Breastfeeding:

• Stimulants excreted in breast milk (low levels)
• Risk-benefit discussion
• Monitor infant for irritability, poor feeding

Older Adults:

• Increased cardiovascular risk; careful cardiac assessment
• Start with lower doses; slower titration
• Consider drug interactions with other medications
• May have good response with careful monitoring

Comorbid Substance Use Disorder:

• Stabilise SUD before ADHD treatment if severe
• Consider non-stimulants first
• If stimulants needed: long-acting/prodrug formulations preferred
• Supervised dispensing may be appropriate
• ADHD treatment may reduce relapse risk [17]

---

8. Comorbidity Management

Common Comorbidities and Treatment Approach

Clinical Pearl: The Anxiety-ADHD Paradox: Many patients and clinicians fear stimulants will worsen anxiety. In practice, when genuine ADHD underlies anxiety (anxious about performance, forgetting, relationships), treating ADHD often reduces anxiety substantially. Start at low doses and titrate slowly, but do not avoid treating ADHD because of comorbid anxiety.

---

9. Functional Impacts

Occupational Impacts

Workplace Accommodations:

• Flexible working hours
• Quiet workspace; reduced distractions
• Written instructions; checklists
• Regular check-ins and deadlines
• Movement breaks
• Use of technology (reminders, apps)

Relationship Impacts

Driving and Safety

• Motor vehicle accidents: 1.5-2x increased risk [19]
• Traffic violations: Significantly increased
• Mechanism: Inattention, impulsivity, risk-taking
• Treatment effect: Medication significantly reduces accident risk

Quality of Life

Adults with ADHD report significantly lower quality of life across all domains. [20] Treatment improves:

• Self-esteem
• Occupational functioning
• Relationship satisfaction
• Physical health behaviours
• Financial stability

---

10. Complications of Treatment

Stimulant-Related Complications

Atomoxetine-Specific Complications

• Hepatotoxicity: Rare but serious; monitor for jaundice
• Suicidal ideation: Black box warning; monitor early treatment
• Urinary hesitancy: Common; usually mild
• Sexual dysfunction: May occur
• Slow onset: 4-6 weeks for full effect; counsel patients

---

11. Prognosis & Outcomes

Natural History

• Symptom persistence: 50-65% meet full criteria in adulthood; 70-80% have residual symptoms [2]
• Symptom evolution: Hyperactivity diminishes; inattention persists; executive dysfunction prominent
• Functional trajectory: Untreated ADHD associated with cumulative impairment across decades
• Mortality: Modestly increased mortality risk, primarily through accidents and comorbidities

Treatment Outcomes

Prognostic Factors

Good Prognosis:

• Early diagnosis and treatment
• Good medication response
• Higher IQ and education
• Supportive relationships
• Employment/structure
• Absence of comorbidities
• Good insight and adherence

Poor Prognosis:

• Late diagnosis
• Poor treatment response
• Comorbid conduct disorder (childhood)
• Comorbid substance use disorder
• Comorbid personality disorder
• Adverse childhood experiences
• Social isolation

---

12. Viva and Examination Focus

Common Exam Questions

Q1: How would you diagnose ADHD in an adult?

"Adult ADHD diagnosis requires demonstrating DSM-5 criteria are met, with particular attention to the childhood onset requirement—symptoms must have been present before age 12. I would take a detailed developmental history, seeking collateral information from parents or school reports where possible. I would use standardised instruments such as the DIVA-5 structured interview and ASRS screening scale. Importantly, I would conduct a comprehensive differential diagnosis assessment, screening for anxiety, depression, bipolar disorder, substance use, and other conditions that can mimic ADHD. Pre-treatment assessment includes cardiovascular risk evaluation with blood pressure, heart rate, and ECG if indicated."

Q2: What are the key differential diagnoses for adult ADHD?

"The key differential diagnoses include generalised anxiety disorder, where worry-driven poor concentration differs from chronic ADHD-pattern inattention; major depressive disorder, where concentration difficulties are episodic and accompanied by neurovegetative symptoms; bipolar disorder, characterised by distinct mood episodes rather than chronic symptoms; substance use disorders, where symptoms relate to intoxication or withdrawal; and sleep disorders causing daytime inattention. The critical differentiator is that ADHD symptoms must have been present before age 12 and are chronic rather than episodic."

Q3: How do you approach stimulant prescribing in someone with a history of substance misuse?

"This requires careful risk-benefit assessment. If active substance use disorder is present, I would prioritise addiction treatment and stabilisation first. For ADHD treatment, I would consider non-stimulant options such as atomoxetine as first-line. If stimulants are needed due to inadequate response, I would use long-acting formulations or prodrugs like lisdexamfetamine, which have lower abuse potential. I would implement monitoring strategies including random drug screens and supervised dispensing if appropriate. Importantly, evidence suggests that treating ADHD appropriately may reduce rather than increase substance use relapse risk."

Model Viva Answers

Viva Point: Opening Statement: "Adult ADHD is a neurodevelopmental disorder characterised by persistent inattention, hyperactivity, and impulsivity causing functional impairment. It affects 2.5-4% of adults, with symptoms required to be present before age 12. It is highly heritable at 70-80% and involves dopaminergic and noradrenergic dysfunction in prefrontal circuits. First-line treatment is lisdexamfetamine, with 70-80% of patients responding to stimulants."

Key Facts to Cite:

• Prevalence: 2.5-4.4% adults (Faraone 2021)
• Persistence: 50-65% from childhood (Faraone 2006)
• Heritability: 70-80%
• Treatment response: 70-80% to stimulants
• Onset criterion: Before age 12 (DSM-5)

Common Mistakes (What Gets You Failed)

❌ Failing to establish childhood onset: ADHD cannot be diagnosed without symptoms before age 12

❌ Missing cardiovascular assessment: Not checking BP/HR before stimulants; not asking about cardiac history

❌ Ignoring substance misuse: Not assessing abuse potential; prescribing stimulants without appropriate safeguards

❌ Dismissing comorbidity: Assuming one diagnosis explains everything; missing anxiety, depression, bipolar

❌ Outdated treatment knowledge: Not knowing lisdexamfetamine is NICE first-line for adults

❌ Treating ADHD without functional impairment: Diagnosis requires impairment, not just symptoms

---

13. Evidence & Guidelines

Key Guidelines

Landmark Studies

Cortese et al. (2018) - Lancet Psychiatry Network Meta-Analysis [5]

• 133 RCTs; 14,346 adults with ADHD
• Key finding: Amphetamines most efficacious (SMD 0.79)
• Key finding: Methylphenidate second (SMD 0.49)
• Clinical impact: Established evidence base for pharmacotherapy

Faraone et al. (2021) - Worldwide Prevalence Meta-Analysis [3]

• Systematic review and meta-regression
• Key finding: 2.58% adult prevalence (95% CI 2.00-3.27)
• Clinical impact: Established adult ADHD as common condition

MTA Cooperative Group (1999) - Multimodal Treatment Study [21]

• 579 children; 14-month RCT
• Key finding: Medication superior to behavioural therapy alone
• Clinical impact: Established stimulants as cornerstone treatment

Chang et al. (2017) - ADHD and Mortality [12]

• Swedish population cohort; 2.6 million individuals
• Key finding: ADHD associated with increased mortality
• Key finding: Medication reduced mortality risk
• Clinical impact: Emphasised importance of treatment

---

14. Patient/Layperson Explanation

What is Adult ADHD?

ADHD is a brain-based condition that affects concentration, organisation, and impulse control. Although it starts in childhood, many people are not diagnosed until adulthood—sometimes because they developed strategies to cope, or because their ADHD was mistaken for other problems like anxiety or depression.

Adult ADHD is NOT about being lazy, unintelligent, or having a character flaw. People with ADHD often have brains that struggle with "boring" tasks but can hyperfocus on interesting ones. They may have brilliant ideas but struggle to complete projects, or know exactly what they should do but find it almost impossible to make themselves do it.

How is Adult ADHD Diagnosed?

Diagnosis involves a detailed assessment by a specialist. Importantly, symptoms must have been present since childhood (before age 12), so the assessment includes questions about your childhood, and often information from parents or old school reports. There is no single test for ADHD—diagnosis is made by a specialist after careful evaluation.

How is it Treated?

1. Medication: Most people with ADHD benefit significantly from medication. The most effective medications are stimulants (lisdexamfetamine, methylphenidate). Despite the name, they don't make you "hyper"—they help your brain focus better. Non-stimulant options are also available.

2. Therapy and Coaching: Cognitive behavioural therapy adapted for ADHD helps develop practical strategies. ADHD coaching focuses on organisation, time management, and goal achievement.

3. Lifestyle: Regular exercise, good sleep habits, structured routines, and breaking tasks into smaller steps all help manage symptoms.

What to Expect from Treatment

• Medication often works within days to weeks
• Finding the right medication and dose takes time
• Side effects (reduced appetite, difficulty sleeping) often improve or can be managed
• Many people describe effective treatment as "life-changing"—being able to complete tasks, maintain relationships, and reach their potential

When to Seek Help

Contact your doctor if:

• Medication is not helping or causing significant problems
• You're experiencing significant anxiety, depression, or thoughts of self-harm
• You have chest pain, palpitations, or cardiovascular symptoms
• You're pregnant or planning pregnancy
• You want to discuss changes to your medication

---

15. References

Primary Guidelines

1. Kooij JJS, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14-34. doi:10.1016/j.eurpsy.2018.11.001

Epidemiology and Natural History

2. Faraone SV, et al. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. doi:10.1017/S003329170500471X

3. Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818. doi:10.1016/j.neubiorev.2021.01.022

4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

Treatment Evidence

5. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4

6. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management (NG87). 2018 (updated 2019). https://www.nice.org.uk/guidance/ng87

Demographics and Sex Differences

7. Hinshaw SP, et al. Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. J Child Psychol Psychiatry. 2022;63(4):484-496. doi:10.1111/jcpp.13480

Genetics and Neurobiology

8. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562-575. doi:10.1038/s41380-018-0070-0

Comorbidity

9. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. doi:10.1176/ajp.2006.163.4.716

10. Adler LA, et al. Efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder and comorbid anxiety. J Clin Psychopharmacol. 2009;29(1):44-50. doi:10.1097/JCP.0b013e318192dcf2

Functional Outcomes

11. Barkley RA, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111(2):279-289. doi:10.1037/0021-843X.111.2.279

12. Chang Z, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2017;74(6):617-623. doi:10.1001/jamapsychiatry.2017.0659

13. Daley D, et al. Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. J Child Psychol Psychiatry. 2018;59(9):932-947. doi:10.1111/jcpp.12825

Environmental Risk Factors

14. Thapar A, et al. Practitioner Review: What have we learnt about the causes of ADHD? J Child Psychol Psychiatry. 2013;54(1):3-16. doi:10.1111/j.1469-7610.2012.02611.x

Neurobiology

15. Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69(12):e89-e99. doi:10.1016/j.biopsych.2011.01.027

16. Shaw P, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA. 2007;104(49):19649-19654. doi:10.1073/pnas.0707741104

Substance Use

17. Humphreys KL, et al. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70(7):740-749. doi:10.1001/jamapsychiatry.2013.1273

Psychological Treatment

18. Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psychiatr Clin North Am. 2010;33(3):497-509. doi:10.1016/j.psc.2010.04.001

Driving Safety

19. Chang Z, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74(6):597-603. doi:10.1001/jamapsychiatry.2017.0659

Quality of Life

20. Brod M, et al. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006;15(1):117-129. doi:10.1007/s11136-005-8325-z

Landmark Trials

21. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086. doi:10.1001/archpsyc.56.12.1073

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Consult a psychiatrist or ADHD specialist for diagnosis and treatment.